HMPL-506

Hutchmed · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	HMPL-506
Also known as	Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study
Sponsor	Hutchmed
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HMPL-506 CI brief — competitive landscape report
HMPL-506 updates RSS · CI watch RSS
Hutchmed portfolio CI